Effect of depemokimab on asthma control and clinical outcomes: a systematic review and meta-analysis of randomized controlled trials.
Shun Nakahara, Maria Júlia Hallack Moura, Sumeyye K Cengiz et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effects of depemokimab on asthma control and clinical outcomes in patients with eosinophilic asthma. Analyzing data from four randomized controlled trials involving 954 participants, the study found that while depemokimab significantly reduced asthma exacerbation rates (IRR 0.47; 95% CI 0.36 to 0.59; p < 0.001), it did not significantly improve asthma control as measured by the ACQ-5.
Key findings
- Depemokimab reduced asthma exacerbation rates with an incidence rate ratio of 0.47.
- No significant improvement in ACQ-5 scores was observed (MD -0.30; p = 0.23).
- SGRQ scores improved modestly but did not reach the minimal clinically important difference (MD -2.80; p = 0.033).
- Safety profile of depemokimab was comparable to placebo.
Why it matters
Understanding the efficacy of new treatments like depemokimab is crucial for managing eosinophilic asthma, particularly in patients who struggle with exacerbations despite standard therapies. This study highlights the need for ongoing evaluation of symptom control and quality of life improvements.